1-3 of 3
Taylor Bucy
Close
Sort by
Journal Articles

Samples from patients with AML show high concordance in detection of mutations by NGS at local institutions vs central laboratories

Clinical Trials & Observations
Uma Borate, Fei Yang, Richard Press, Amy S. Ruppert, Dan Jones, Sean Caruthers, Weiqiang Zhao, Jo-Anne Vergilio, Dean C. Pavlick, Luke Juckett, Brianna Norris, Taylor Bucy, Amy Burd, Eytan M. Stein, Prapti Patel, Maria R. Baer, Wendy Stock, Gary Schiller, William Blum, Tibor Kovacsovics, Mark Litzow, James Foran, Nyla A. Heerema, Leonard Rosenberg, Sonja Marcus, Ashley Yocum, Mona Stefanos, Brian Druker, John C. Byrd, Ross L. Levine, Alice Mims
Journal: Blood Advances
Blood Adv (2023) 7 (20): 6048–6054.
https://doi.org/10.1182/bloodadvances.2022009008
Published: 2023
Includes: Supplemental data
Journal Articles

Patients with FLT3-mutant AML needed to enroll on FLT3-targeted therapeutic clinical trials

Clinical Trials & Observations
Taylor Bucy, John M. Zoscak, III, Motomi Mori, Uma Borate
Journal: Blood Advances
Blood Adv (2019) 3 (23): 4055–4064.
https://doi.org/10.1182/bloodadvances.2019000532
Published: 2019
Includes: Supplemental data
Journal Articles

Representation of therapy-related myelodysplastic syndrome in clinical trials over the past 20 years

Uma Borate, Brianna A. Norris, Abby Statler, Rongwei Fu, Taylor Bucy, Mikkael A. Sekeres
Journal: Blood Advances
Blood Adv (2019) 3 (18): 2738–2747.
https://doi.org/10.1182/bloodadvances.2019000293
Published: 2019